LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Slides:



Advertisements
Similar presentations
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Advertisements

ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
NICE –CG 181 Continuum of CVD Risk and its treatment
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
AIM HIGH Niacin plus Statin to prevent vascular events
PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.
The Latest Lipid Guidelines:
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Cholesteryl Ester Transfer Protein Inhibitors
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
What Do We Know About LDL-C?
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
62-year-old Man With Unstable Angina
PCSK9 Inhibitors and Cardiovascular Outcomes
% decrease in LDL-C at 24 weeks from baseline
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
A Patient Journey Through Statin Intolerance
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Monoclonal Antibodies in CVD: What Does the Future Hold?
Advances in Hypertriglyceridemia Treatment
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Préparation ESC Septembre
Ezetimibe/simvastatin
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Reducing Risk for CV Outcomes
Potential mechanisms whereby statins may reduce the risk of stroke
A Family Affair.
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Addressing Cardiovascular Events:
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Lipids, the Heart, and the Kidney
LDL-c reductions below 1
PCSK9 Inhibitors and Real-World Evidence
Presentation transcript:

The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

LDL-C Goals

Impact of Intensive Statin Therapy on Major Vascular Events

ENHANCE: Ezetimibe Lowers LDL-C Levels but Not Progression of Atherosclerosis

IMPROVE-IT: Ezetimibe/Simvastatin Combination vs Simvastatin Monotherapy

Coronary Drug Project: Niacin Associated With Reduction in Mortality in Men

AIM-HIGH: Niacin Improves Lipids but Not CV Events

Incidence of Muscle Adverse Effects

Statins in Patients With Dementia

ARIC: Reduced CHD Incidence in Individuals With PCSK9 Loss-of-Function Mutations

Horus: Atherosclerosis in Ancient Egypt

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk (FOURIER)

ODYSSEY Outcomes: Phase 3 Post-ACS With SAR236553

REVEAL Trial

ACCELERATE Trial

Homozygous FH: Novel Treatments

FH

Thank you for participating in this activity

Abbreviations

Abbreviations (cont)

References

References (cont)

References (Cont)

References (Cont)